Skip to main content
TipRanks
Go Ultimate75% OFF

Immunocore Holdings (IMCR) Drug Pipeline

258 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Imc-P115cCancer, Hla-A*02:01-Positive, Prame PositivePhase IRecruitingStudy of IMC-P115C in Advanced PRAME-Positive CancersAug 26, 2025―
Imc-R117c, Chemotherapy Drug, Kinase Inhibitor, Antiangiogenic Agent, Monoclonal AntibodyCancer, Hla-A*02:01-Positivephase1AndPhase2RecruitingPhase 1/2 Study of IMC-R117C in Selected Advanced CancersFeb 05, 2025―
Nivolumab, Nivolumab + Relatlimab, BrenetafuspAdvanced MelanomaPhase IIIRecruitingIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)Oct 19, 2023―
Tebentafusp, Tebentafusp With Pembrolizumab, Investigators ChoiceAdvanced MelanomaPhase IIIRecruitingTebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)Aug 26, 2022―
Brenetafusp, Brenetafusp And Pembrolizumab, Brenetafusp And Chemotherapy, Brenetafusp And Monoclonal Antibodies And Chemotherapy, Brenetafusp And Tebentafusp, Brenetafusp And Bevacizumab, Brenetafusp And Kinase InhibitorsSelect Advanced Solid Tumorsphase1AndPhase2RecruitingSafety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsJan 30, 2020―
Pembrolizumab, Ipilimumab, Dacarbazine, Imcgp100Uveal MelanomaPhase IIActive Not RecruitingSafety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaFeb 14, 2017―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Immunocore Holdings Plc (IMCR) have in its pipeline
Immunocore Holdings IMCR is currently developing the following drugs: Imc-P115c, Imc-R117c, Chemotherapy Drug, Kinase Inhibitor, Antiangiogenic Agent, Monoclonal Antibody, Nivolumab, Nivolumab + Relatlimab, Brenetafusp, Tebentafusp, Tebentafusp With Pembrolizumab, Investigators Choice, Brenetafusp, Brenetafusp And Pembrolizumab, Brenetafusp And Chemotherapy, Brenetafusp And Monoclonal Antibodies And Chemotherapy, Brenetafusp And Tebentafusp, Brenetafusp And Bevacizumab, Brenetafusp And Kinase Inhibitors, Pembrolizumab, Ipilimumab, Dacarbazine, Imcgp100. These drug candidates are in various stages of clinical development as the company works toward FDA approval.